After Bionano Genomics announced preliminary Q4 results and updated on its "ELEVATE!" objectives, Ladenburg analyst Jeffrey Cohen said he was "encouraged" by the company’s progress through 2022 and sees additional growth drivers in 2023. The analyst, who thinks the company’s commitment to expanding clinical data will support reimbursement and commercial efforts, reiterates a Buy rating and $8 price target on Bionano shares.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BNGO:
- Bionano Genomics to Host Strategy Day on February 2, 2023 in New York City
- Bionano Genomics initiated with an Outperform, $4 target at Scotiabank
- Bionano Genomics sees FY22 revenue $27.7M-$28M, consensus $27.44M
- Bionano Genomics sees Q4 revenue of $8.1M-$8.4M, consensus $7.85M
- Bionano Genomics Reports Preliminary Fourth Quarter and Full-Year 2022 Results
